This study was aimed at finding predictors of invasive fungal infection (IFI) after pediatric allogeneic hematopoietic SCT (HSCT). All children who received allogeneic HSCT in the Wilhelmina Children's Hospital Utrecht between 2004 and 2012 were included. HSCT data were prospectively collected. Patients were retrospectively classified into high-or low-risk groups for developing IFI using criteria based on available literature. Predictors for the occurrence of IFI were analyzed using Cox regression models. We used logistic regression models to analyze the association between other HSCT-related complications and IFI. Secondary outcomes were overall survival and treatment-related mortality (TRM). Two-hundred nine patients were included in the analysis; median age was 6.6 years. The cumulative incidence of IFI was 12%. In patients classified as 'low risk' (n ¼ 75), only 5.3% developed IFI (odds ratio (OR): 0.325; P ¼ 0.047). In multivariate analysis, a predictor for the occurrence of IFI was an a priori determined HSCT TRM risk 420% (based on EBMT-risk score). Post-HSCT, the administration of high-dose steroids was associated with IFI (OR: 4.458; P ¼ 0.010). Patients who developed IFI showed an increased risk of TRM (OR: 3.773; P ¼ 0.004). These results confirm that risk group stratification should guide intensity of monitoring for IFI and use of antifungal prophylaxis.
INTRODUCTION
Invasive fungal infection (IFI) remains an important cause of mortality among hematopoietic SCT (HSCT) recipients, in whom the natural defense mechanisms are weakened by underlying disease, conditioning regimens and immunosuppressive agents. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Based on prior studies, IFI is estimated to occur in 8-17% of pediatric HSCT patients, with a mortality rate of 35-50%. [1] [2] [3] [4] [5] [6] Incidence varies in the different post-transplant phases, with peaks both pre-and post-engraftment. 7, 11 Invasive aspergillosis, invasive candidiasis and zygomycosis are the most common types of IFI. 9, 11, 12 Prophylactic use of new antifungal agents and better monitoring options may impact the incidence of fungal infections and associated mortality. 13, 14, 19 Signs and symptoms of IFI are seldom characteristic, leading to late recognition of the disease and subsequently worse outcomes. 15 Universal use of prophylactic antifungal medication for all transplant recipients will result in toxicity and drug interactions. In low-risk patients, this will not outweigh the benefit of reducing the IFI risk. Instead, it is essential to identify those who are most at risk and target antifungal prophylaxis and monitoring on this group of patients. Therefore, this study was aimed to find predictors of IFI after pediatric allogeneic HSCT.
Previous studies found predictors of IFI to include age at SCT 410, diagnoses such as severe aplastic anemia and AML and relapse of original disease. [1] [2] [3] [4] [5] [6] Post-HSCT, GVHD, viral reactivations and use of high-dose steroids are possibly related to the occurrence of IFI. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] However, studies that focus on pediatric patients are scarce, use relatively small cohorts and are possibly outdated as advances in prophylactic and diagnostic strategies have been made. Therefore, we performed a risk factor analysis on a large cohort of pediatric patients from a single center.
PATIENTS AND METHODS

Patient selection
Patients who received allogeneic HSCT, irrespective of the indication, between 1st January 2004 and 31st July 2012 in the Wilhelmina Children's Hospital (of the UMC Utrecht) were included. HSCT data were prospectively collected in the TRIASUS database. Data were captured from the database on 31st October 2012. For patients who underwent multiple HSCT's, only last HSCT's were included. This study was approved by the institutional ethical committee in agreement with the Helsinki Declaration of 1975, revised in 2008. All patients or their legal representatives gave informed consent.
Transplant details and conditioning HLA-matching was based on high-resolution typing for class I and class II (10 alleles) for BM or PBSC donors. For cord blood (CB) donors, intermediate resolution criteria were used (low resolution for loci HLA-A, -B and -DRB1 by high-resolution typing). A HLA-DPB1 mismatch was not taken into account. For the analyses, patients were divided into a matched group and a mismatched group, with one or more allele or Ags mismatches defined as a mismatch. CB grafts were considered matched (six Ags) when they were identical according to the aforementioned intermediate resolution criteria. All patients received conditioning according to applicable international and national protocols.
as used in our institution, was based on available literature [1] [2] [3] [4] [5] [6] and includes pre-and post-HSCT criteria. For this study, we retrospectively classified all patients into high-or low-risk groups using the same criteria. Patients who were classified into the low-risk group pre-HSCT could develop complications that would reassign them into the high-risk group (for example, development of acute GVHD).
In some cases, the type of prophylaxis was switched due to toxicity. Alternative antifungal agents included liposomal amphotericin-B (Abelcet or Ambisome), caspofungin and posaconazole (42010).
From 2004 until 2006, serum galactomannan (GM) analysis was performed in case of clinical suspicion for fungal infection. From 2006 onwards, all patients were twice weekly monitored by GM analysis during the first 4 months after HSCT. GM was interpreted to be positive for values 40.5 ng/ml in two subsequent samples. In addition, from 2008 onwards a pre-SCT bronchoalveolar lavage sample was taken from all patients undergoing HSCT.
Empirical antifungal therapy with voriconazole (trough level targeted) was started in the event of unexplained fever with negative bacterial cultures during neutropenia 472 h. If there was evidence suggesting fungal infection other than Aspergillus, or invasive yeast infection, liposomal amphotericin-B (Ambisome 5 mg/kg) was given.
GVHD prophylaxis and treatment
All patients received CsA as GVHD prophylaxis (dosage based on plasma levels of 100-250 ug/L). In recipients of unrelated marrow transplants, MTX was added (10 mg/m 2 on day þ 1, þ 3 and þ 6 after HSCT) and in unrelated CB recipients prednisolon (1 mg/kg until day þ 28 after HSCT). Serotherapy with anti-thymocyte globulin was administered to recipients of unrelated donor transplants.
Acute GVHD (aGVHD) was staged using Glucksberg criteria. 16 For grade I aGVHD and limited chronic GVHD (cGVHD), local corticosteroid therapy was given. Patients who developed aGVHD Xgrade II were primarily treated with prednisone in a dosage of 2 mg/kg/day (p.o. or i.v.). In cases of steroid refractory GVHD, mesenchymal stroma cell infusion was used as second-line treatment (42005). Patients who developed extensive cGVHD were treated with prednisone in a dosage of 2 mg/kg/day (p.o.). In case of failure, fludarabin (30 mg/m 2 : every 3 weeks for a maximum of six times) and in some cases either rituximab or Imatinib (for scleroderma skin or bronchilitits obliterans) was added. If the patient still received CsA, this was replaced by tacrolimus and/or sirolimus was added. Patients were classified as having received 'high-dose steroids' when they developed aGVHD Xgrade II, extensive cGVHD or alloimmune lung disease.
Treatment-related mortality risk
Retrospectively, the risk of treatment-related mortality (TRM) was calculated for each patient based on the EBMT-risk score. 17 Scoring Date of IFI was defined as the date on which the first diagnostic test (either microbiological or radiological) was positive. Patients who were diagnosed with IFI pre-HSCT were included in the analysis and identified as probable or proven IFI if there was obvious clinical progression of the infection post-SCT. Date of IFI for these patients was the date on which disease progression occurred.
Other (secondary) outcomes were overall survival (OS) and TRM.
Statistical analysis
Possible predictors for the occurrence of IFI were analyzed using Cox proportional hazard models. Factors that were analyzed included age at HSCT (using 10 years as a cutoff value for analysis according to prior literature 1, 3 ), gender, TRM risk, diagnosis type, use of mould-active prophylaxis, prior history of IFI, donor type, donor relation and match grade, conditioning regimen, transplant number and positive GM in pre-SCT bronchoalveolar lavage samples. Factors meeting statistical significance (Po0.05) upon univariate analysis were included in multivariate analysis. Results were expressed as hazard ratios (HR) and their corresponding 95-percent confidence intervals (95% CI).
The association of IFI with other complications and neutrophil recovery was analyzed using logistic regression analysis. Factors that were analyzed included aGVHD Xgrade II, extensive cGVHD, viral reactivations including HHV6, EBV, adenovirus and CMV, duration of neutropenia and the administration of high-dose steroids (for any indication). Results were expressed as odds ratios (ORs) and their corresponding 95% CI. The association between occurrence of IFI and mortality (OS and TRM) was evaluated using logistic regression analysis. Confounding factors that were associated with IFI and mortality were corrected for in multivariate analysis. For statistical analysis, SPSS version 20.0 (SPSS Inc, Chicago, IL, USA) was used.
RESULTS
Patient characteristics
Two-hundred and nine patients were included. For all patient-, donor-and transplant characteristics, see Table 1 . The median age at SCT was 6.63 years (range 0.2-22.7). A total of 50.2% of our study patients (n ¼ 105) were treated for malignant disease, the other 49.8% were non-malignant (n ¼ 104). Donors used were 98 unrelated CB (46.9%), 54 family/sibling donor (25.8%) and 57 unrelated marrow (27.3%). HLA-matched donors were used in 129 patients (61.7%). No patients were excluded from analyses.
Incidence of IFI The cumulative incidence of proven (n ¼ 11, 5.3%) and probable (n ¼ 14, 6.7%) IFI was 12% (n ¼ 25). The incidence of IFI over the years is shown in Figure 1 . Among the 25 IFI patients, 2 had been diagnosed with IFI pre-HSCT and showed disease progression post-HSCT. Of all probable and proven cases of IFI, 15 Table 3 .
Outcome after IFI Of all patients who developed IFI, 52.0% (n ¼ 13) died of treatment-related causes (TRM), versus 14.7% (n ¼ 27) of those who did not develop IFI (OR: 3.773; 95% CI: 1.537-9.265; P ¼ 0.004 after correction for a priori HSCT TRM risk and use of highdose steroids). OS in IFI patients was lower (OR: 0.299; 95% CI: 0.127-0.706; P ¼ 0.006). Within IFI patients, 40% (n ¼ 10) survived; within other patients 69.0% (n ¼ 127) survived (Figure 2) . Of all IFI patients who died (n ¼ 15), 5 died as a direct result of IFI, in 7 patients death was associated with IFI and 3 died of unrelated causes (relapse of original disease or GVHD).
Patients who developed IFI Clinical characteristics of patients in whom IFI occurred are given in Table 4 . Median age at HSCT was 10.7 years (range 1.3-18.1). They underwent HSCT for a range of indications. Five patients had a prior history of probable or proven IFI (Aspergillus spp., n ¼ 2; Candida spp., n ¼ 2, Fusarium spp., n ¼ 1). Eleven patients (44%) developed IFI despite receiving mould-active prophylaxis (voriconazole, n ¼ 8; Abelcet, n ¼ 1; caspofungin, n ¼ 2). In two patients, voriconazole levels were low (o0.5 mg/L); in another patient they were not monitored. In the remaining eight patients, fungal infection occurred despite voriconazole trough levels in the targeted range. In one patient who developed Aspergillus infection during voriconazole prophylaxis, the fungus was shown to be resistant for voriconazole. For the other patients, information on drug resistance is lacking.
DISCUSSION
In this single center pediatric cohort, we found an incidence of IFI of 12%. We demonstrated that risk group stratification for developing IFI using criteria based on available literature correlated well with the actual occurrence of IFI in children after HSCT. An additional predictor found to influence the occurrence of IFI was an estimated a priori HSCT TRM risk 420%. Post-HSCT the use of high-dose steroids was associated with IFI. TRM was higher in patients who developed IFI, even after correction for a priori HSCT TRM risk.
The observed incidence is in line with other studies where incidence rates of 8-17% were reported. [1] [2] [3] [4] [5] [6] We may still have underestimated the true incidence of IFI due to a conservative definition of IFI and the fact that autopsy was not always performed. Interestingly, despite changes in our hospital in prophylactic strategies as of 2008 towards the use of more mould-active antifungal agents, the incidence of IFI did not decrease. Possible causes may be the increasing percentage of high-risk patients being transplanted over the last few years (the proportion of patients with a TRM risk 420% rose from 40 to 60%; data not shown), increasing patient age and better diagnostic tools to identify IFI. 10 Moreover, the increasing incidence of azole-resistant IFI as described by Snelders et al. 20 may partly explain the less than optimal effectivity of our prophylactic strategy.
Patients who were classified into the 'low-risk' group, rarely developed IFI, showing that risk group stratification for developing IFI using criteria based on available literature seems to correlate well with the actual occurrence of IFI. This implies that our focus should be on high-risk patients and optimizing prophylaxis and monitoring within this group.
Despite what previous studies have suggested, 1-6 we were not able to confirm the predictive value of different HSCT indications and age at HSCT, although the latter showed a trend towards significance in our analysis (age 410 years, P ¼ 0.069). The inclusion of 'TRM risk' in the analysis, which is a factor combining both HSCT indication and patient age, might have affected these results. Similarly, prior history of IFI was only borderline significant in multivariate analysis (P ¼ 0.065). Unrelated donor transplant did not show an increased risk for developing IFI.
Our study confirms a strong association between the use of high-dose steroids and the development of IFI, showing that not (immune-mediated) post-HSCT complications by itself, but the treatment they require predisposes for the occurrence of IFI. Alternative GVHD-prophylaxis protocols, other strategies to prevent GVHD and the subsequent use of steroids may impact this. 22, 23 Outcomes of this study are likely to be distorted by the fact that since 2008, patients identified as 'high risk' for IFI were given mould-active prophylaxis. For this reason, the associations we found might be an underestimation of reality.
A substantial part of IFI's that occurred in our population, developed after the patient was no longer neutropenic. Unlike previous reports, 4,10 we did not find neutrophil recovery to be a predictor of IFI. However, other markers of cellular reconstruction can be analyzed for determining their relation to the occurrence of IFI as well. For future research, analysis of the relation between cellular reconstitution (for example, CD4 þ count) and IFI might be a valuable contribution to this study. 21 Additional areas of interest are strategies to improve immune-reconstitution and adjuvant immunotherapies to prevent or treat fungal infections. Although the speed of neutrophil engraftment was not significantly associated to the occurrence of IFI, very early engraftment (o14 days) may impact outcomes, as may the use of combined CB/haploidentical transplants. 24 Furthermore, as we performed a retrospective risk factor analysis, a prospective study to confirm our results is warranted.
In conclusion, we demonstrated that risk group stratification for developing IFI using criteria based on available literature correlated well with the actual occurrence of IFI in children after HSCT. Pre-HSCT predictor was an a priori TRM risk 420%. Post-HSCT the use of high-dose steroids was strongly associated with development of IFI. Risk group stratification should guide intensity of monitoring for IFI and use of antifungal prophylaxis. Novel monitoring, antifungal prophylaxis as well as novel therapeutic options or transplant strategies improving immunereconstitution may impact outcomes, but need to be studied prospectively.
